Madrigal Pharmaceuticals (MDGL) has an average rating of buy and mean price target of $678.18, according to analysts polled by FactSet.
What else is happening in Research?
Research
Update: BofA Upgrades Eldorado Gold to Buy From Underperform, Lifts Price Target to $54 From $32
(Updates with the analyst's commentary.)BofA Securities upgraded Eldorado Gold (EGO) to buy from underperform and raised its price target to $54 from $32.Following the de-risking of Skouries, the company's "flagship growth asset," the brokerage said it expects free cash flow to increase to $1.5 billion in 2027.BofA said it also expects Eldorado's gold production to increase by 29% and all-in sustaining costs to fall by 24% in the same year.Eldorado Gold has an average rating of overweight and mean price target of $47.82, according to analysts polled by FactSet.Price: $44.33, Change: $+1.96, Percent Change: +4.63%
$EGO
Research
HSBC Downgrades Netflix to Hold From Buy, Adjusts Price Target to $76 From $96
Netflix (NFLX) has an average rating of overweight and mean price target of $93.57, according to analysts polled by FactSet.
$NFLX
Research
RBC Capital Markets Downgrades LVMH to Sector Perform Rating, Cuts PT
RBC Capital Markets on Tuesday downgraded luxury goods group LVMH (MC.PA) to sector perform from outperform rating and reduced its price target to 475 euros from 575 euros.
$MC.PA